Amarin raises $100 million to help launch heart drug
(Reuters) - Biopharmaceutical company Amarin Corp Plc said it raised $100 million in non-equity financing that will help it form a sales force to launch its heart drug Vascepa.
Amarin shares, however, fell 22 percent after the bell as the company did not announce a sale or a partnership to market the drug, as some investors had expected.
"This transaction provides Amarin with non-dilutive capital that will ensure our ability to fully execute on the Vascepa product launch while continuing our strategic partnership discussions," CEO Joseph Zakrzewski said in a statement.
The company said it will hire 250 to 300 sales professional to launch Vascepa in the first quarter of 2013.
(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)
- Israel rejects ceasefire plan, source says, as death toll nears 850 |
- White House aide says Republicans might try for Obama impeachment
- First Ebola victim in Sierra Leone capital on the run
- Bad weather seen as probable cause of Air Algerie crash
- EU edges to economic sanctions on Russia but narrows scope |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video